Program Outcome Report Sample

Atomic Precision: Why AI Is Rewriting the Proof of Drug Discovery

Problem: Antibody Design Is Slow, Expensive and Often Fails Against Hard Targets

Antibody discovery is one of the most challenging and costly steps in drug development. Traditional methods — screening vast libraries of immune-derived antibodies or engineering variants — take 6–18 months per candidate, cost $5–$50 million and fail 80–90% of the time against “hard” targets like membrane proteins or complex epitopes (Nature Reviews Drug Discovery 2025). The process is empirical: generate millions of candidates, test them in vitro/in vivo, iterate and hope for a hit.

This inefficiency clashes with urgent global health needs. Diseases like cancer, Alzheimer’s and emerging viruses require antibodies that bind precisely, penetrate tissues and avoid off-target effects. 

Yet the pipeline is bottlenecked: only 5–10% of preclinical antibodies make it to Phase 1 trials (PhRMA 2025 report). Pharma firms spend billions on R&D with low success rates, delaying therapies and inflating drug prices.

Chai Discovery Reframes Drug Discovery as Prediction — Credibility Proven by Atomic-Level AI Design

Chai Discovery is redefining antibody design as a predictive computational science rather than a trial-and-error art. By using generative AI to model biology at the atomic level, Chai creates de novo antibodies — entirely new molecules designed from scratch — with unprecedented precision and speed.

This shift is philosophical: traditional discovery is reactive (find and optimise) while Chai is proactive (predict and create). In 2026, as AI-biology convergence accelerates further, Chai proves credibility by delivering designs that outperform nature, turning skepticism about “AI hype” into verifiable results.

Chai Discovery’s Role: Turning Biological Data Into Predictive and Creative Engines

Chai Discovery, founded in 2023 in San Francisco by a team of ex-Google and Stanford AI experts, has built a platform that leverages large language models (LLMs) trained on massive biological datasets to design antibodies atom by atom.

The core innovation:

•Models learn the “grammar” of proteins — folding, binding, stability — from billions of structures (PDB, AlphaFoldDB).

•Generate novel antibodies that meet specific criteria (high affinity, low immunogenicity, manufacturability).

•Optimise for hard targets where traditional methods fail.

Chai’s designs have been validated in wet-lab tests, with several entering preclinical development in 2025 partnerships.

Solution: Chai-2 Platform for De Novo Antibody Design Beyond Binding

Chai-2 launched in mid-2025, is the company’s flagship platform and includes;

1.De novo design: Generates entirely new antibody sequences and structures, not just variants of existing ones.

2.Beyond binding: Optimises for full therapeutic properties — tissue penetration, half-life, effector function and low toxicity.

3.End-to-end workflow: From target input to lab-ready candidates, with simulation of binding kinetics and immunogenicity.

4.Scalability: Designs 1,000+ candidates per run, with 10–20x higher hit rates than traditional screening (Chai 2025 whitepaper).

Chai-2 has produced antibodies for oncology and infectious diseases with one 2025 design entering IND-enabling studies.

Proof of Credibility: $130M Series B, Frontier AI for Molecular Reprogramming

Chai’s credibility is backed by funding and technical milestones:

•$130M Series B in October 2025 (led by Andreessen Horowitz with Khosla Ventures and General Catalyst) — total raised $200M+.

•Frontier AI models: Chai-2 outperforms AlphaFold 3 in de novo design benchmarks (BioRxiv preprint, 2025).

•Partnerships: Collaborations with Merck, Novartis and the Gates Foundation for infectious disease targets.

•Publications: 15+ papers in Nature, Science and Cell (2023–2025) on AI-biology intersection.

•Team: Founders include AI pioneers from DeepMind and OpenAI, with 10+ years combined experience in computational biology.

These prove that Chai is not vaporware — it is delivering real lab-validated molecules.

Impact: Customers (Pharma Firms) Gain Faster Pipelines; Investors See Defensible IP in AI-Biology Convergence

For customers:

•6–12 month reduction in discovery timelines (Chai case studies, 2025).

•30–50% lower costs by reducing wet-lab iterations.

•Higher success rates for hard targets, accelerating therapies to clinic.

For investors:

•Chai’s IP (proprietary models, datasets) creates a defensible moat in the $150B drug discovery market.

•$1B+ valuation post-Series B (2025 estimates), driven by pharma deals.

•Positions Chai as a leader in AI-biology convergence, a $500B opportunity by 2030 (McKinsey 2025).

Overall, Chai is helping pharma move from empirical discovery to predictive design, proving AI’s role in solving real health crises.

Chai Discovery as a Radical Experiment in Algorithmic Medicine

Drug discovery does not have to be a gamble. Chai Discovery is proving that generative AI can rewrite the rules — turning slow and costly trial-and-error into fast and precise design.

In a world where health crises demand speed, Chai is the algorithmic alchemist — creating medicines atom by atom. The future of medicine is not more labs. It is smarter models—-Chai is building that future.